Roche Glycart

Switzerland
Schlieren, Zurich, Switzerland, CH-8952

Company profile

Roche Glycart company profile

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

Business identity

Phone number
+41447556161
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Founded
2000-01-01, Year

Headquarters

Postal code
CH-8952
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
1
Total equity funding
$13.6M
Last funding
Series A / $13.6M / 2003-11-26
Last equity funding
Series A / $13.6M
Investors
7
Lead investors
2
Founders
1
Articles
8
Exited on
2005-07-19

Founders and investors

Founders

Joel Jean Mairet

Lead investors

Gilde HealthcareGlobal Life Science Ventures

Investors

BioMedPartnersForbion Capital PartnersGilde HealthcareGlobal Life Science VenturesNovartis Venture Fund